Source comparison
NAD+ BPC-157 Stack Cellular Repair Protocol 2026: Research Grade Stack Comparison
Primary Mechanism Mitochondrial NAD+ replenishment → sirtuin activation → enhanced ATP production and DNA repair VEGF upregulation → angiogenesis → increased vascular supply and collagen deposition Dual-pathway: metabolic restoration + structural repair simult
This comparison does not assign a generated winner or score.
- Primary Mechanism
- Mitochondrial NAD+ replenishment → sirtuin activation → enhanced ATP production and DNA repair
- VEGF upregulation → angiogenesis → increased vascular supply and collagen deposition
- Dual-pathway: metabolic restoration + structural repair simultaneously
- Combined protocol addresses both energy deficits and tissue damage. The two primary bottlenecks in cellular recovery
- Typical Research Dosing
- NMN 250–500mg oral daily OR NAD+ 50–100mg subcutaneous 2–3x/week
- BPC-157 250–500mcg subcutaneous twice daily
- Both compounds administered concurrently. No interaction between pathways
- NAD+ morning dosing + BPC-157 split AM/PM maintains stable plasma levels across both pathways
- Observable Timeline
- 2–4 weeks for subjective energy improvements; 8–12 weeks for mitochondrial biogenesis markers
- 4–8 weeks for tissue repair acceleration in injury models; sustained effects require ongoing administration
- 8–12 weeks minimum to observe synergistic cellular-level changes in combined protocol
- Single-compound protocols plateau around week 8–10; dual-pathway stacks sustain progressive improvements beyond 12 weeks
- Primary Research Application
- Mitochondrial dysfunction, aging-related energy decline, neurodegenerative models, metabolic disorders
- Tendon/ligament injury, gastrointestinal mucosal damage, post-surgical recovery, chronic inflammation
- Comprehensive cellular repair in contexts requiring both metabolic and structural restoration
- Most effective in scenarios where energy deficits and tissue damage co-exist. Common in aging, chronic disease, and recovery contexts
- Cost per 12-Week Protocol
- $180–$400 (oral precursors) or $600–$1200 (subcutaneous NAD+)
- $300–$600 (BPC-157 at 500mcg/day for 12 weeks)
- $480–$1800 combined depending on NAD+ delivery method
- Subcutaneous NAD+ is the most expensive component; oral NMN/NR significantly reduces total protocol cost